Erion Dobi

Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial.

Antonio Llombart‐Cussac, Catherine Harper‐Wynne, Antonia Perelló et al. · Journal of Clinical Oncology · 2023 · 72 citations

Medicine, Oncology, Pharmacology +17

Impact of STAT3 Phosphorylation on the Clinical Effectiveness of Anti-EGFR–Based Therapy in Patients With Metastatic Colorectal Cancer

Erion Dobi, Franck Monnien, Stéfano Kim et al. · Clinical Colorectal Cancer · 2012 · 42 citations · Full text

Medicine, Oncology, Pharmacology +17

Incidence and risk factors of anemia in patients with early breast cancer treated by adjuvant chemotherapy

Natacha Chaumard, Samuel Limat, Cristian Villanueva et al. · The Breast · 2011 · 32 citations

Medicine, Oncology, Pharmacology +13

Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab

Quentin Jacquinot, Nathalie Méneveau, Antoine Falcoz et al. · Frontiers in Cardiovascular Medicine · 2022 · 26 citations · Full text

Medicine, Cardiology, Breast Oncology +16

In the Era of Genomics, Should Tumor Size Be Reconsidered as a Criterion for Neoadjuvant Chemotherapy?

Xavier Pivot, Laura Mansi, L. Chaigneau et al. · The Oncologist · 2015 · 24 citations · Full text

Medicine, Oncology, Breast Oncology +16